-
Nov 7, 2024 | 
onclive.com | Matthew Powell
CommentaryVideoNovember 7, 2024Author(s):Matthew Powell, MD, discusses the FDA approval of dostarlimab plus chemotherapy for patients with advanced or recurrent endometrial cancer. Matthew Powell, MD, Ira C.
-
Sep 4, 2024 | 
onclive.com | Matthew Powell
CommentaryVideoSeptember 4, 2024Author(s):Matthew Powell, MD, discusses the FDA approval of dostarlimab plus chemotherapy for patients with advanced or recurrent endometrial cancer. Matthew Powell, MD, the Ira C.
-
Sep 4, 2024 | 
jdsupra.com | Matthew Powell
Price collusion is in the news lately, but it’s not the backroom deals between managers that is the focus for enforcement officials and legislators. There has been a spate of legislation and lawsuits targeting the use of software that gives visibility to competitors’ prices. This allows firms to adjust their prices, either undercutting the competition or setting a de facto floor.
-
Mar 29, 2024 | 
onclive.com | Matthew Powell
Overall Survival in Patients With Primary Advanced or Recurrent Endometrial Cancer Treated With Dostarlimab Plus Chemotherapy in Part 1 of the ENGOT-EN6-NSGO/GOG-3031/RUBY TrialMatthew Powell, MD, presents findings from a second interim analysis of part 1 from the ENGOT-EN6-NSGO/GOG-3031/RUBY trial investigating the combination of dostarlimab-gxly plus carboplatin/paclitaxel compared with placebo/chemotherapy in patients with primary advanced or recurrent endometrial cancer.
-
Jan 24, 2024 | 
targetedonc.com | Matthew Powell
Matthew A.
-
Dec 26, 2023 | 
onclive.com | Matthew Powell
Floor Backes, MD, closes the discussion by explaining that endometrial cancer care is rapidly evolving and complicated, requiring calling on colleagues for guidance, getting molecular profiling, and encouraging trial participation.
-
Dec 26, 2023 | 
onclive.com | Matthew Powell
Unmet Needs in the Management of Patients With Advanced Endometrial CancerLooking ahead, Floor Backes, MD, notes that key needs in the treatment of advanced endometrial cancer are figuring out next steps when immunotherapy resistance develops, targeted radiation for oligometastatic disease, and sorting patients into subgroups for personalize care.
-
Dec 11, 2023 | 
onclive.com | Matthew Powell
Data From the AtTEnd: Study: Atezolizumab Plus Carboplatin and Paclitaxel for Treatment of Advanced Endometrial CancerDrs Powell and Backes discuss additional immunotherapy trial results from ESMO 2023 including AtTEnd and DUO-E, noting differences across trials likely due to patient population composition rather than drug differences, and need for caution with PARP inhibitor maintenance.
-
Dec 4, 2023 | 
onclive.com | Matthew Powell
Dr Ganesan on the Use of ctDNA Assays For MRD Detection in Cancer CareDr Habib on Developments in Palliative Care For Patients With CancerDr Boland on the Emergence of KRAS G12C Inhibitors in mCRCDr In on the Increased Incidence of Gastric Cancer in Minority Patient Populations
-
Nov 27, 2023 | 
onclive.com | Matthew Powell
Dr Boland on the Emergence of KRAS G12C Inhibitors in mCRCDr In on the Increased Incidence of Gastric Cancer in Minority Patient PopulationsDr Ecker on the Investigation of the Microbiome in Pancreatic Cancer
